5 results
Primary objective:To determine the safety and tolerability of multiple, once-daily oral doses of CNP520 over 13 weeks in healthy elderly subjectsSafety: ECG, vital signs and laboratory data; assessment of cognitive function; dermatological…
PrimaryTo assess the efficacy of ravulizumab in the treatment of participants with TMASecondaryTo characterize TMA responseTo assess impact on hemoglobin levels To evaluate change in kidney function To assess duration of Complete TMA Response and…
The purpose of this study is to determine the effect of treatment on cognition, overall clinical status and underlying pathology in subjects with a risk of occurrence of the first clinical symptoms of Alzheimer's disease.People without…
In this study we want to evaluate the safety and efficacy of the new drug ZPL389. ZPL389 is tested in various strengths in patients with moderate or severe atopic dermatitis. The effects of ZPL389 are compared with those of a placebo.
To assess the efficacy of ravulizumab versus placebo in the treatment of adult and adolescent participants with HSCT-TMA.